Intravenous apomorphine therapy in Parkinson's disease clinical and pharmacokinetic observations

Brain

Volumn 124, Issue 2, 2001, Pages 331-340

  Manson, A J ^a,b   Hanagasi, H ^a,b   Turner, K ^a,b   Patsalos, P N ^c   Carey, P ^d   Ratnaraj, N ^c   Lees, A J ^a,b,e  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HAREFIELD HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apomorphine; Central venous catheter; Intravenous; Parkinson's disease

Indexed keywords

APOMORPHINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG DISTRIBUTION; DYSKINESIA; FEMALE; HUMAN; INDWELLING CATHETER; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOSIS;

EID: 0035125765     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/124.2.331     Document Type: Article

References (52)

1. Panniculitis in association with apomorphine infusion
2. Totally implantable, permanent central venous catheter systems in AIDS patients - A method for home care or an unacceptable infection risk?
3. Levodopa-induced dyskinesia: Facts and fancy. What does the MPTP monkey model tell us?
4. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
5. Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
6. Rationale for continuous dopaminomimetic therapy of Parkinson's disease
7. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease
8. Clinical usefulness of apomorphine in movement disorders
9. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease
10. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment
11. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists
12. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias
13. Subcutaneous apomorphine in the treatment of Parkinson's disease
14. Apomorphine infusional therapy in Parkinson's disease: Clinical utility and lack of tolerance
15. Peripheral pharmacokinetics of apomorphine in humans
16. Apomorphine tolerance in Parkinson's disease: Lack of a dose effect
17. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
18. Motor response following repeated apomorphine administration is reduced in Parkinson's disease
19. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study
20. Kurtzke scales revisited: The application of psychometric methods to clinical intuition
21. Pharmacokinetics of apomorphine in Parkinson's disease: Plasma and cerebrospinal fluid levels in relation to motor responses
22. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years
23. Suppression of L-DOPA induced dyskinesias by subcutaneous infusions of apomorphine
24. Implantable catheter systems. Experiences with 1000 patients with central venous ports
25. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity
26. Dopamine agonists in Parkinson's disease: A look at apomorphine
27. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
28. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys
29. Individual-patient monitoring in clinical practice: Are available health status surveys adequate?
30. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease
31. Pharmacokinetics of apomorphine in parkinsonian patients
32. The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport
33. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease
34. Lisuride infusion pump: A device for the treatment of motor fluctuations in Parkinson's disease
35. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias
36. Subcutaneous apomorphine in late stage Parkinson's disease: A long term follow up
37. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients
38. External and implanted pumps for apomorphine infusion in parkinsonism
39. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans
40. Plasma concentration of levodopa in patients with Parkinson's disease
41. Apomorphine induced cognitive changes in Parkinson's disease
42. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease
43. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease
44. Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease
45. Strategies for treating patients With advanced Parkinson's disease with disastrous fluctuations and dyskinesias
46. Implantable venous access system for apomorphine infusion in complicated Parkinson's disease
47. Implantable venous access system for apomorphine infusion in parkinsonian patients: Three year follow up
48. Patterns of clinical response and plasma dopa levels in Parkinson's disease
49. The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study
50. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications
51. Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter
52. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease